Current Report Filing (8-k)
April 04 2022 - 6:01AM
Edgar (US Regulatory)
0001444307
false
0001444307
2022-04-01
2022-04-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): April 1, 2022
ONCOSEC
MEDICAL INCORPORATED
(Exact
Name of Registrant as Specified in Charter)
Nevada |
|
000-54318 |
|
98-0573252 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
24
North Main Street
Pennington,
NJ 08534-2218
(Address
of Principal Executive Office)
(855)
662-6732
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act. |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act. |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange Act. |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act. |
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
ONCS |
|
NASDAQ
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Events.
On
April 1, 2022, OncoSec Medical Incorporated (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”)
confirming that the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) that requires companies listed on Nasdaq to maintain
a minimum bid price of at least $1.00 per share to ensure continued listing (the “Listing Requirement”). The Company regained
compliance with the Listing Requirement after the closing bid price for its common stock listed on Nasdaq equaled or exceeded $1.00 per
share for 10 consecutive business days. The Company will remain in compliance with this Listing Requirement as long as the minimum bid
price of its common stock does not fall below $1.00 for 30 consecutive business days. There can be no assurances that the Company will
remain in compliance with the Listing Requirement.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
ONCOSEC
MEDICAL INCORPORATED |
|
(Registrant) |
|
|
|
Date:
April 1, 2022 |
By: |
/s/
Kevin Smith |
|
Name: |
Kevin
Smith |
|
Title: |
Interim
President and Chief Executive Officer |
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Aug 2024 to Sep 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Sep 2023 to Sep 2024